Literature DB >> 22098042

Does memantine improve the gait of individuals with Alzheimer's disease?

Olivier Beauchet, Gilles Allali, Cyrille Launay, Bruno Fantino, Cédric Annweiler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22098042     DOI： 10.1111/j.1532-5415.2011.03648.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  9 in total

Review 1.  Management of Gait Changes and Fall Risk in MCI and Dementia.

Authors:  Gilles Allali; Joe Verghese
Journal:  Curr Treat Options Neurol       Date:  2017-09       Impact factor: 3.598

2.  Gait changes with anti-dementia drugs: a prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease.

Authors:  Olivier Beauchet; Cyrille P Launay; Gilles Allali; François R Herrmann; Cedric Annweiler
Journal:  Drugs Aging       Date:  2014-05       Impact factor: 3.923

3.  Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis.

Authors:  O Beauchet; C P Launay; G Allali; C Annweiler
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

Review 4.  Gait and cognition: a complementary approach to understanding brain function and the risk of falling.

Authors:  Manuel Montero-Odasso; Joe Verghese; Olivier Beauchet; Jeffrey M Hausdorff
Journal:  J Am Geriatr Soc       Date:  2012-10-30       Impact factor: 5.562

5.  Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial.

Authors:  Cédric Annweiler; Bruno Fantino; Elsa Parot-Schinkel; Samuel Thiery; Jennifer Gautier; Olivier Beauchet
Journal:  Trials       Date:  2011-10-20       Impact factor: 2.279

6.  Memantine for dementia.

Authors:  Rupert McShane; Maggie J Westby; Emmert Roberts; Neda Minakaran; Lon Schneider; Lucy E Farrimond; Nicola Maayan; Jennifer Ware; Jean Debarros
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

7.  Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease.

Authors:  Hideki Shimura; Aiba Saiko; Akito Hayashi; Nobutaka Hattori; Takao Urabe
Journal:  BMC Neurol       Date:  2021-02-10       Impact factor: 2.474

Review 8.  Motoric Cognitive Risk Syndrome: Symptoms, Pathology, Diagnosis, and Recovery.

Authors:  Ke Xiang; Yin Liu; Li Sun
Journal:  Front Aging Neurosci       Date:  2022-02-02       Impact factor: 5.750

9.  Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study.

Authors:  Olivier Beauchet; Cyrille P Launay; Gazan Allali; Gilles Watfa; Karim Gallouj; François R Herrmann; Cédric Annweiler
Journal:  BMC Neurol       Date:  2013-11-21       Impact factor: 2.474
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.